This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Mar 9;381(9869):785-7.

doi: 10.1016/S0140-6736(12)62194-1.

The beginning of the end for serogroup B meningococcus?

Matthew D Snape¹, Andrew J Pollard

Affiliations

PMID: 23324564
DOI: 10.1016/S0140-6736(12)62194-1

Comment

The beginning of the end for serogroup B meningococcus?

Matthew D Snape et al. Lancet. 2013.

. 2013 Mar 9;381(9869):785-7.

doi: 10.1016/S0140-6736(12)62194-1.

Authors

Matthew D Snape¹, Andrew J Pollard

Affiliation

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK. matthew.snape@paediatrics.ox.ac.uk

PMID: 23324564
DOI: 10.1016/S0140-6736(12)62194-1

No abstract available

PubMed Disclaimer

Comment on

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Vesikari T, et al. Lancet. 2013 Mar 9;381(9869):825-35. doi: 10.1016/S0140-6736(12)61961-8. Lancet. 2013. PMID: 23324563 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information